301258.SZ
Suzhou Fushilai Pharmaceutical Co., Ltd.
SZSE · C 制造业 · CN
CNY 26.06
−1.62%Year over year
Reported trailing growth
- Revenue
- -7.6%
- EBITDA
- —
- EBIT
- +8.6%
- EPS
- +8.9%
- Free cash flow
- -59.8%
- Operating cash flow
- +42.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.7%
- EBITDA
- -21.3%
- EBIT
- -28.1%
- Net income
- -28.7%
- EPS
- -29.9%
- Free cash flow
- -37.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026